A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Trial Profile

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2017 According to a MimiVax media release, interim data analysis from this trial has been completed.
    • 06 Apr 2017 Planned End Date changed from 2 Apr 2018 to 2 Apr 2019.
    • 06 Apr 2017 Planned primary completion date changed from 2 Apr 2017 to 2 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top